Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114893 · ClinicalTrials.gov registry record · Phase 2
Travoprost Five Day Posology Study
A Phase 2 study of Ocular Hypertension and Open Angle Glaucoma (OAG), sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01114893: Completed Phase 2 study of Ocular Hypertension and Open Angle Glaucoma (OAG), sponsored by Alcon Research.
NCT01114893 is a Phase 2 study of Ocular Hypertension and Open Angle Glaucoma (OAG) that has completed, run by Alcon Research. The registered enrollment target is 60 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114893, a Phase 2 study of Ocular Hypertension and Open Angle Glaucoma (OAG), has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
Primary Outcome
Outcome measure shows how each treatment reduced eye pressure at 8 AM on Day 5 compared to the eye pressure at 8 AM before the start of treatment
Conditions Studied
Interventions
- DRUG Travoprost 0.004%
- DRUG Travoprost Vehicle
- DRUG Travoprost (Groups A, B and C)
Study Locations (1)
Texas
- Contact Alcon Call Center For Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-04 |
| Phase | Phase 2 |
What the finished NCT01114893 record still lists
NCT01114893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Travoprost 0.004% is the first listed.
NCT01114893 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01114893 about?
NCT01114893 is a clinical study titled "Travoprost Five Day Posology Study". The purpose of this study is to determine the safety and efficacy of three concentrations of travoprost ophthalmic solution (Groups A, B and C) administered eight times daily.
What is the current status of trial NCT01114893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-04.
What conditions does trial NCT01114893 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma (OAG).
What interventions are being tested in trial NCT01114893?
The interventions under investigation include: Travoprost 0.004% (DRUG), Travoprost Vehicle (DRUG), Travoprost (Groups A, B and C) (DRUG).
Who is sponsoring clinical trial NCT01114893?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01114893 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01114893's enrollment target sits among peer trials
60 43rd of 54 higher than 10 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
RECRUITING · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
-
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia